Citation Impact
Citing Papers
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer
2017
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
2021 StandoutScienceNobel
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
2017
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
2017
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
2017 Standout
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy
2017
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
2017 Science
Cancer statistics, 2022
2022 Standout
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2017
Cancer immunotherapies targeting the PD-1 signaling pathway
2017 StandoutNobel
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
2016
Cancer Statistics, 2021
2021 Standout
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Combinatorial Cancer Immunotherapies
2016
From tumour heterogeneity to advances in precision treatment of colorectal cancer
2016
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis
2015
Combination cancer immunotherapy and new immunomodulatory targets
2015
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
2016
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer
2017
Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?
2017
Guillain-Barré syndrome
2016 Standout
Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
2018 Standout
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
2017
Nasopharyngeal carcinoma
2019 Standout
Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
2018
T Cell Dysfunction in Cancer
2018
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
2016
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
2017
Lung cancer: current therapies and new targeted treatments
2016 Standout
Colorectal cancer
2019 Standout
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
2017 Standout
Immunotherapy in colorectal cancer: rationale, challenges and potential
2019
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
2019
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
2016
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
2018
Current state of immunotherapy for non-small cell lung cancer
2007
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
2016 Standout
Current understanding of the human microbiome
2018 Standout
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
2017
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
2016 Standout
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
2015
EGFR tyrosine kinase inhibitorsversuschemotherapy inEGFRwild-type pre-treated advanced nonsmall cell lung cancer in daily practice
2017
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
2017
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
2016
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
2017
<em>nab</em>-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
2016
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
2017
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
2022
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
2016
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
2017
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
2016
Cornerstones of CRISPR–Cas in drug discovery and therapy
2016 StandoutNobel
Gene-expression profiling to predict responsiveness to immunotherapy
2016
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
2016
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
2017
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Next generation predictive biomarkers for immune checkpoint inhibition
2016
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Hepatocellular carcinoma
2022 Standout
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
2018 Standout
The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System
2017
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Immune checkpoint inhibitors: new strategies to checkmate cancer
2017
Immunotherapy for Colorectal Cancer
2017
Bladder Cancer
2020 Standout
Breast Cancer Treatment
2019 Standout
The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis
2016
Size matters: Dissecting key parameters for panel‐based tumor mutational burden analysis
2018
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
2017 Standout
Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis
2017
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
2016
Chimeric Antigen Receptor Therapy
2018 Standout
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
2018
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
2018
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
2017
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
2018
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
2016
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
2018
Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?
2016
Medical Management of Brain Metastases and Leptomeningeal Disease in Patients with Breast Carcinoma
2018
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
2015
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Works of Daniel Waterkamp being referenced
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
2013
14LBA Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR)
2015
Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC).
2015
Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC
2017
Abstract 2651: Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma
2016
Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC
2016
Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study.
2017
Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).
2015
Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
2015
Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).
2016
Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR.
2016
Abstract P2-11-06: Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer
2016
Safety and Efficacy of Mpdl3280A (Anti-Pdl1) in Combination with Bevacizumab (Bev) and/or Chemotherapy (Chemo) in Patients (Pts) with Locally Advanced or Metastatic Solid Tumors
2014
Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).
2015
Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC
2016
OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients
2017